Targeting the mutation in gliomas by CRISPR/Cas precision base editing.

Publikation

Targeting the mutation in gliomas by CRISPR/Cas precision base editing.

Wissenschaftlicher Artikel/Review - 02.11.2024

Weber Remi, Vasella Flavio, Klimko Artsiom, Silginer Manuela, Lamfers Martine, Neidert Marian Christoph, Regli Luca, Schwank Gerald, Weller Michael

Zitation

Weber R, Vasella F, Klimko A, Silginer M, Lamfers M, Neidert M, Regli L, Schwank G, Weller M. Targeting the mutation in gliomas by CRISPR/Cas precision base editing. Neurooncol Adv 2024; 6:vdae182.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Neurooncol Adv 2024; 6

Veröffentlichungsdatum

02.11.2024

eISSN (Online)

2632-2498

Seiten

vdae182

Kurzbeschreibung/Zielsetzung

Gliomas, the most frequent malignant primary brain tumors, lack curative treatments. Understanding glioma-specific molecular alterations is crucial to develop novel therapies. Among them, the biological consequences of the isocitrate dehydrogenase 1 gene mutation ( ) remain inconclusive despite its early occurrence and widespread expression.